This summer, communities throughout the country are experiencing periods of intense heat, and there’s more to come.

Lung conditions, like asthma and chronic obstructive pulmonary disease, are more common in women than men. Stephanie Harris ...

COPD, or chronic obstructive pulmonary disease, affects more than 30 million Americans, yet many have never heard of it. COPD ...

Background Antimicrobial resistance (AMR) is a growing global health crisis and is particularly relevant to people living ...

Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive ...

Today, on World Bronchiectasis Day, the American Lung Association is launching a new campaign to support people living with bronchiectasis, which is a chronic and progressive lung condition that ...

Synchrony Medical announced that it received FDA 510 (k) clearance for its LibAirty airway clearance system.

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

Dietary approaches are shaping up as a key aspect of chronic obstructive pulmonary disease (COPD) management.

Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.